pre-IPO PHARMA

COMPANY OVERVIEW

ArriVent is dedicated to accelerating the global development of innovative biopharmaceutical products. With a deep, global network of biotechs and big Pharmas, ArriVent has access to unique and best-in-class drug candidates at various development stages, including those coming from China and other emerging biotech hubs. Through strategic collaborations with innovative biopharma companies, ArriVent aims to globalize medicines for patients with a broad range of diseases, with an initial focus in oncology.


LOCATION

  • Newton Square, PA, USA

  • THERAPEUTIC AREAS

  • Oncology

  • WEBSITE

    https://arrivent.com/


    CAREER WEBSITE

    https://arrivent.com/#careers


    SOCIAL MEDIA


    INVESTORS



    PRESS RELEASES


    Jul 5, 2022

    ArriVent Biopharma Announces First Patient Enrolled in Global Phase 1b Trial of Furmonertinib in Advanced or Metastatic Non-Small Cell Lung Cancer with EGFR or HER2 Mutations


    Feb 15, 2022

    ArriVent Biopharma Appoints Bahija Jallal to its Board of Directors


    Jun 30, 2021

    ArriVent Biopharma Launches with Up To $150M in Series A Financing and Strategic Licensing Agreement for Clinical-Stage Oncology Asset


    Aug 20, 2019

    Les célébrations des 100 ans du CN arrivent à Vancouver dans le cadre du Pacific National Exhibition


    Jul 4, 2019

    Les célébrations des 100 ans du CN arrivent à Calgary


    For More Press Releases


    Google Analytics Alternative